Preliminary findings in a phase I clinical trial of blinatumomab and nivolumab in adults with relapsed/refractory (R/R) CD19 positive B-ALL demonstrated favorable safety profile and clearance of MRD in this heavily pretreated cohort (28). Here, CD19 is linked to acute lymphoblastic leukemia.